Baba M, Ayoola Y, Abdul H, Goni B, Mairari F
Niger Med J. 2024; 65(4):465-478.
PMID: 39398397
PMC: 11470279.
DOI: 10.60787/nmj-v65i3-497.
Wolfes J, Kirchner L, Doldi F, Wegner F, Rath B, Eckardt L
Cardiovasc Toxicol. 2024; 24(7):656-666.
PMID: 38851664
PMC: 11211193.
DOI: 10.1007/s12012-024-09872-3.
Mu X, Duan Y, Xu Q, Wang S, Gao G, Han N
Front Pharmacol. 2023; 14:1268597.
PMID: 38027007
PMC: 10643644.
DOI: 10.3389/fphar.2023.1268597.
Alomar F, Tian C, Bidasee S, Venn Z, Schroder E, Palermo N
Int J Mol Sci. 2023; 24(1).
PMID: 36613717
PMC: 9820108.
DOI: 10.3390/ijms24010274.
Saadeh K, Nantha Kumar N, Fazmin I, Edling C, Jeevaratnam K
Br J Pharmacol. 2022; 179(24):5237-5258.
PMID: 36165125
PMC: 9828855.
DOI: 10.1111/bph.15959.
Effects of COVID-19 on Arrhythmia.
Zhan Y, Yue H, Liang W, Wu Z
J Cardiovasc Dev Dis. 2022; 9(9).
PMID: 36135437
PMC: 9504579.
DOI: 10.3390/jcdd9090292.
Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV.
Wu K, Woldu B, Post W, Hays A
Curr Opin HIV AIDS. 2022; 17(5):261-269.
PMID: 35938459
PMC: 9365326.
DOI: 10.1097/COH.0000000000000753.
Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-à-go-go-Related Gene and Cav1.2.
Zheng Z, Cai D, Fu Y, Wang Y, Song Y, Lian J
Front Pharmacol. 2022; 13:889713.
PMID: 35873575
PMC: 9301601.
DOI: 10.3389/fphar.2022.889713.
COVID-19: treatments and the potential for cardiotoxicity.
Birkhoelzer S, Cowan E, Guha K
Br J Cardiol. 2022; 28(1):7.
PMID: 35747481
PMC: 8822515.
DOI: 10.5837/bjc.2021.007.
Transcriptional Effects of Candidate COVID-19 Treatments on Cardiac Myocytes.
Jakobi T, Gross J, Cyganek L, Doroudgar S
Front Cardiovasc Med. 2022; 9:844441.
PMID: 35686037
PMC: 9170897.
DOI: 10.3389/fcvm.2022.844441.
Outcomes of implantable cardioverter-defibrillator implantation in HIV-infected patients: A single-center retrospective cohort study.
Narla V, Yang H, Li Q
Clin Cardiol. 2022; 45(8):857-863.
PMID: 35642740
PMC: 9346971.
DOI: 10.1002/clc.23868.
Antipsychotic Polypharmacy-Related Cardiovascular Morbidity and Mortality: A Comprehensive Review.
Edinoff A, Ellis E, Nussdorf L, Hill T, Cornett E, Kaye A
Neurol Int. 2022; 14(1):294-309.
PMID: 35324580
PMC: 8954521.
DOI: 10.3390/neurolint14010024.
Antiviral and anti-inflammatory drugs to combat COVID-19: Effects on cardiac ion channels and risk of ventricular arrhythmias.
Cubeddu L, de la Rosa D, Ameruoso M
Bioimpacts. 2022; 12(1):9-20.
PMID: 35087712
PMC: 8783084.
DOI: 10.34172/bi.2021.23630.
QTc prolongation in patients with COVID-19: a retrospective chart review.
Pornwattanakavee S, Priksri W, Leelakanok N
Transl Clin Pharmacol. 2022; 29(4):197-205.
PMID: 35024360
PMC: 8718354.
DOI: 10.12793/tcp.2021.29.e20.
Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data.
Thomas L, Birangal S, Ray R, Miraj S, Munisamy M, Varma M
Ther Adv Drug Saf. 2021; 12:20420986211041277.
PMID: 34471515
PMC: 8404633.
DOI: 10.1177/20420986211041277.
Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review.
Ridjab D, Ivan I, Budiman F, Juliawati D
Medicine (Baltimore). 2021; 100(31):e26787.
PMID: 34397829
PMC: 8341216.
DOI: 10.1097/MD.0000000000026787.
Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents.
Shah S, Hariharan U, Chawla R
J Anaesthesiol Clin Pharmacol. 2021; 37(2):160-170.
PMID: 34349362
PMC: 8289657.
DOI: 10.4103/joacp.JOACP_461_20.
Association between exposure to Efavirenz and substrates of dysrhythmia in HIV-infected young adults.
Hosseini Z, Mollazadeh R, Dehghan-Manshadi S, Mohebi M, Eslami M, Sadre-Bafghi S
Clin Cardiol. 2021; 44(10):1448-1456.
PMID: 34328227
PMC: 8495077.
DOI: 10.1002/clc.23705.
Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget.
Al-Moubarak E, Sharifi M, Hancox J
Front Cardiovasc Med. 2021; 8:645172.
PMID: 34017865
PMC: 8129016.
DOI: 10.3389/fcvm.2021.645172.
Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies.
Gatti M, De Ponti F, Pea F
CNS Drugs. 2021; 35(4):345-384.
PMID: 33866523
PMC: 8053373.
DOI: 10.1007/s40263-021-00811-2.